Yan Martha Putri

Yan Martha Putri is more than just a name trending on Google; she represents a shift in Indonesian consumer consciousness. In a market flooded with drop-shippers and fake gurus, she offers a return to .

1. Retinal Health and Age-Related Macular Degeneration (AMD)

assessing the knowledge, attitudes, and practices regarding cervical cancer and HPV vaccination among medical students in Jakarta. Methodology Expertise: She has a strong background in performing data curation investigation statistical analysis for systematic reviews. summary of a specific research paper she authored, or are you looking for her contact information for a professional inquiry?

Born in Bogor on July 4, 1993, Martha Putri had a passion for the aviation industry. Her career as a flight attendant spanned approximately four years, during which she worked for two different airlines. She started at Batik Air in 2014, where she worked for three years. yan martha putri

Right now, I’m choosing to be proud of the small things. I’m proud that I showed up here to write. I’m proud that I watered my plants before they wilted. I’m proud that I said “no” to something that drained my energy.

Investigated the effectiveness of different treatment regimens (Pro re nata vs. fixed) for aflibercept administration in patients with age-related macular degeneration. Idiopathic Choroidal Neovascularization: Researched risk factors such as large choroidal vessels Oncology & Public Health: Cervical Cancer & HPV: cross-sectional study

Yan Martha Putri is more than just a viral moment; she is a budding brand. Whether she is acting in a web series, modeling for a fashion shoot, or making her followers laugh with a regional joke, she maintains a consistency of character that is rare in the fast-paced world of social media. As she continues to evolve from an internet star to a mainstream entertainer, one thing is clear: we will be seeing much more of Yan Martha Putri in the years to come. Yan Martha Putri is more than just a

at RS Murni Teguh Sudirman Jakarta (August 2022 – June 2023).

Her trajectory suggests she will move from being a "content creator" to a for SMEs in the Indonesian halal industry—a sector projected to be worth billions in the coming decade.

Dr. Putri has also directed her research efforts toward women’s health in developing nations. She contributed significantly to a cross-sectional study tracking the among medical students in Jakarta, published in the Open Access Macedonian Journal of Medical Sciences . By identifying gaps in oncology education among future doctors, her work advocates for stronger public health interventions and preventive immunization strategies to reduce the burden of cervical cancer. Clinical Portfolio and Patient Care Born in Bogor on July 4, 1993, Martha

One of Dr. Putri’s most prominent scientific contributions is her research on , a leading cause of severe central vision loss worldwide. Co-authoring studies alongside senior specialists like Andi Arus Victor, her work evaluates the efficiency of advanced anti-vascular endothelial growth factor (anti-VEGF) treatments.

Moreover, Yan Martha Putri's popularity highlights the global nature of online culture. Despite being an Indonesian individual, she has managed to attract a significant following worldwide, transcending geographical and cultural boundaries. This phenomenon speaks to the interconnectedness of the internet, where individuals from diverse backgrounds can come together to share and discover new ideas.

This study, "Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis," used rigorous methods to analyze the outcomes of existing clinical trials. The analysis showed that a fixed, bimonthly injection schedule of aflibercept was superior to an "as needed" (pro re nata) approach, leading to better visual acuity improvements after 12 months, with the standardized mean difference of 0.56 (95% CI 0.36–0.75, I² = 0%, p < 0.00001). The choice of aflibercept is significant as it was a relatively new anti-VEGF therapy at the time, and establishing optimal dosing schedules has important implications for patient outcomes.